Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
Clinical trial NCT02609984 · TERMINATED
Trial details
- NCT number
- NCT02609984
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-29
- Primary completion
- 2019-02-06
- Enrollment
- 89
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.